A recent systematic study on the use of intravitreal injections and subthreshold MPL to treat macular edema was published by Gawecki, showing that subthreshold diode micropulse laser plus anti-VEGF therapy may require fewer intravitreal injections than anti-VEGF monotherapy with equivalent functional and morphological outcomes [41]. The gene discussed is VEGFA; the disease is macular retinal edema.